CMC Biologics Names New CEO

CMC Biologics Inc., a commercial manufacturer of therapeutic proteins with operations in Copenhagen, Denmark; Seattle, WA; and Berkeley, CA, has named Gustavo Mahler as its chief executive officer, effective January 1, 2016. The company has 500 employees globally, and offers fully integrated, biopharmaceutical process development and manufacturing services for clinical and commercially launched biological medicines.

Mr. Mahler has more that 20 years of executive management experience in biologics manufacturing and development. He joined the company as head of the Seattle facility in 2008, was promoted to president of U.S. operations and then became the chief operating officer for the company’s global operations.

“This transition of Gustavo taking over the CEO responsibility from Claes Glassell has been planned for a long time. We are excited that Gustavo can continue the leadership of the company through a seamless transition,” said David Kauffmann, chairman of the board, CMC Biologics, and managing partner, European Equity Partners. “Claes has been with CMC Biologics for more than 10 years, first as a board director and as CEO since 2011. He will continue as a board director and we are grateful for his commitment and the industrial experience he brought to the company. Claes will continue to assist CMC Biologics in its growth and continued success.”

“Leading the CMC Biologics executive team is a great privilege at this moment in our history where the company maintains world leadership as a biologics CDMO offering services for both products in development and in market. The company is experiencing strong growth, which is a testament to the company’s world-class service offering, management and science team,” said Mr. Mahler.

Prior to joining CMC Biologics, Mr. Mahler was head of manufacturing at the Bayer Healthcare biotechnology plant in Berkeley, CA. He worked for 15 years at Bayer in the U.S., Europe and Latin America serving in various manufacturing and management positions. He received his PhD in biochemistry from the University of Buenos Aires, and has a Master of Business Administration degree from the University UNED of Madrid and an Executive Certification in Management from MIT Sloan.